We also identify JAK mutations as common shared mediators of tumorigenesis across the spectrum of PTCL which remain important exploitable targets for targeted therapeutics, such as the like of JAK inhibitors which generate anti-tumoral effects via inhibition of the JAK-STAT signaling pathway for tumor suppression. Here, SOAT1 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.